This phase I trial is combining a new drug (blinatumomab) with a commonly used immunotherapy drug (pembrolizumab) for the treatment of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
This trial is treating patients with Diffuse Large B-Cell Lymphoma (DLBCL).
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Commercial Sponsor
AMGEN
Summary
In this trial, participants will be allocated to one of seven cohorts. Treatment commencement will be dependent on the cohort to which the participant is allocated. The aim of this trial is to determine the maximum tolerated dose of blinatumomab, so participants will receive varying doses between cohorts.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More